Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized) |
|
| Oxycodone | Experimental | Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized) |
|
| Cannabis (THC:CBD = ~1:0) | Experimental | Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized) |
|
| Cannabis (THC:CBD = ~ 0:1) | Experimental | Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized) |
|
| Cannabis (THC:CBD = ~ 1:1) | Experimental | Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxycodone | Drug | Oxycodone, 2.5 mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| Subjective Effects | Participants will rate "drug liking", "good drug effects", and "high" on a visual analogue scale (VAS; 1-100mm). | 6 weeks |
| Cold Pressor Test | Participants will immerse their hand in a bucket of ice water to determine pain threshold and pain tolerance latencies (in seconds). | 6 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Caroline A Cooper, PhD | New York Psychiatric Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| New York State Psychiatric Institute | New York | New York | 10032 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D019966 | Substance-Related Disorders |
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D010098 | Oxycodone |
| C587251 | nabiximols |
| ID | Term |
|---|---|
| D003061 | Codeine |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
Not provided
Not provided
This is a randomized, cross-over, double-blind, placebo-controlled study. All participants will partake in each arm and receive all interventions.
Not provided
Not provided
Not provided
| Cannabis (THC:CBD = ~1:0) + Oxycodone |
| Experimental |
Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized) |
|
| Cannabis (THC:CBD = ~ 0:1) + Oxycodone | Experimental | Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized) |
|
| Cannabis (THC:CBD = ~ 1:1) + Oxycodone | Experimental | Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized) |
|
| Cannabis (THC:CBD = ~ 1:0) | Drug | Cannabis with high THC concentration and negligible CBD concentrations |
|
| Cannabis (THC:CBD = ~ 0:1) | Drug | Cannabis with high CBD concentration and negligible THC concentrations |
|
| Cannabis (THC:CBD = ~ 1:1) | Drug | Cannabis with equivalent CBD and THC concentrations |
|
| Placebo | Drug | Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone |
|
|
| D001523 | Mental Disorders |
| D000470 |
| Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |